The increase in deal flow seen in 2021 continued through into 2022
There was a significant increase in deal volumes in H1 2022 vs the same period in 2021
Despite a slowdown in economic activity, deal count remained stable in 2022 with 88 deals – a slight increase from 2021
Sources: CG Results analysis, CapitalIQ, Mergermarket
Interest among PE within the pharma commercialisation services sector remained positive; however, falling macro-economic confidence led to fewer PE deals in Q3 and Q4
Market access: Pricing reimbursement market access; HEOR: Health economics and outcomes researchSources: CG Results analysis, CapitalIQ, Mergermarket
Companies in bold represent private equity firms. Sources: Public data, CapitalIQ, Mergermarket = only publicly disclosed deals are shown